The Scientist explored the work of a researcher who had an unexpected finding while developing a novel anti-tau therapy.

A common medication may help prevent dementia and Alzheimer's disease—but researchers are still trying to figure out why, and ...

Axsome Therapeutics said it would submit its Alzheimer’s disease treatment for FDA approval despite mixed results from two ...

The first pill to slow down the progression of Alzheimer’s disease is being studied for use on the NHS. Regulators are due to ...

The Alzheimer’s Association — a Chicago-based nonprofit committed to Alzheimer’s research, care and support — shared its top ...

Ta-1505 is under clinical development by Merck and currently in Phase I for Alzheimer’s Disease. According to GlobalData, Phase I drugs for Alzheimer’s Disease have a 63% phase transition success rate ...

The small miracles that 2024 brought to our lives lay the groundwork for new revolutionary treatments that are being prepared ...

As the year comes to a close, experts from the Alzheimer's Association reflect on some of the hopeful advances in diagnosis, ...

ASN-90 is under clinical development by Asceneuron and currently in Phase I for Alzheimer’s Disease. According to GlobalData, Phase I drugs for Alzheimer’s Disease have a 63% phase transition success ...

SCIENTISTS investigating Alzheimer’s disease have made a key breakthrough, identifying a key cellular process that drives ...

Even as new drugs come to market, further study appears to point to infections as a possible cause for the debilitating ...

Alzheimer's is the most common cause of dementia and researchers say their findings could lead to treatments that could slow ...